Forest Laboratories, Inc. Reports Fiscal Year First Quarter 2013 Earnings Per Share of $0.21 –

Teflaro® (ceftaroline fosamil), a broad-spectrum bactericidal cephalosporin antibiotic for the treatment of adults with community-acquired bacterial pneumonia and with acute bacterial skin and skin structure infections, recorded sales of $9.4 million.

Leave a Reply

Your email address will not be published.